Global law firm Freshfields has advised Fresenius Kabi AG on the divestment of Fresenius Kabi’s Calea homecare business in Canada to Capital Health Partners (CHP). The transaction includes the sale of four sites across the country.

Fresenius is a global healthcare company headquartered in Bad Homburg, Germany, focusing on the therapy and care of critically and chronically ill patients. The company is committed to improving healthcare through the use of technology and human care and operates in more than 90 countries worldwide.

Fresenius Kabi will continue to supply the Canadian market with its broad product portfolio, remaining a close partner to health care delivery in the country. At the same time, the company continues to reduce complexity and optimize utilization in its global network.

Freshfields has advised Fresenius on all legal aspects of the transaction, working closely with an integrated Fresenius’ in-house legal team including Jan Winzen (Head of Legal M&A/Transformation), Vera Burdenski (Legal Project Lead), Lukas Fleck (Legal Counsel), Pablo Bassols (Legal Head Region International) and Terry Reid (Sr. Director Legal and Compliance, Canada). In-house tax advice was provided by Saska Stanic (Senior Manager International Tax).

The Freshfields team is led by Partners Olga Stürmer (Frankfurt) and Lars Meyer (Frankfurt/Berlin) and Principal Associate Laura Ashoff (Berlin) with support by Associate Benedikt Grosch (Frankfurt, all Corporate/M&A).

The core team further includes Christoph Werkmeister (IP/Data & Tech, Düsseldorf), Uta Itzen (Competition Law, Düsseldorf), Mariusz Motyka-Mojkowski (Competition Law, Berlin), Philipp Dohnke (Global Transactions, IP/IT, Hamburg) as well as Marius Scherb (Global Transactions, IP/IT, Hamburg) and Lena Klenk (Global Transactions, Data & Tech, Frankfurt).

The advice on Tax Law matters was provided by Christian Ruoff, Tobias Franz and Kevin Schröder (all Hamburg).

Freshfields has supported Fresenius on several significant transactions in recent years, including two bond issues totaling €1.3bn (press release here) and a further €1bn bond issuance (press release here), as well as the divestment of the Eugin fertility services group to a consortium led by IVI RMA (press release here).